The preliminary Q2 results confirm strong commercial momentum in the core HIFU business, and the divestiture of non-core segments simplifies the investment narrative. The full Q2 2026 report on August 13 will be critical for EPS, cash flow, and updated guidance. Traders should watch for the full report and conference call for confirmation of profitability trajectory and any updates on the BPH/endometriosis pipeline catalysts.
Price Chart
Executive Summary
FocalTherics (formerly EDAP TMS) reported preliminary Q2 2026 HIFU revenue of $12.7M-$13.2M (+34-39% YoY), a record quarter, and announced the classification of its legacy ESWL and Distribution segments as discontinued operations, effectively becoming a pure-play robotic focal therapy company. The company also provided updates on its pipeline expansion into BPH and endometriosis, and highlighted a proposed +11.6% Medicare payment increase for HIFU in 2027. The strong preliminary results and strategic refocusing are positive, but the lack of full financials (EPS, operating cash flow) and the ongoing operating losses temper the bullishness.
Key Facts
- Preliminary Q2 2026 HIFU revenue of $12.7M to $13.2M, representing 34% to 39% YoY growth.
- Record 13 Focal One system sales in Q2 2026, up 44% YoY.
- Global installed base of Focal One systems reached 184, up from 146 in Q2 2025.
- U.S. Focal One procedure volume grew 47% YoY.
- HIFU gross margin improved to 54%-56%, up 300-500 bps YoY.
- ESWL and Distribution segments classified as held for sale and reported as discontinued operations, making the company a pure-play HIFU business.
- Cash, cash equivalents, and short-term investments were $21.5M as of June 30, 2026, after drawing €12.0M from its EIB credit facility in April 2026.
- Proposed +11.6% Medicare payment increase for HIFU (CPT 55880) to $10,797 in CY 2027.
- Company advancing Focal One for BPH (IRB-approved U.S. feasibility study) and endometriosis (FDA Breakthrough Device Designation, limited European commercial launch).
- Full Q2 2026 financial results to be reported after market close on August 13, 2026.
Financial Impact
Preliminary Q2 HIFU revenue $12.7M-$13.2M (34-39% YoY growth); HIFU gross margin 54-56%; cash position $21.5M
Risk Factors
- Preliminary results are unaudited and subject to change in the full Q2 filing.
- Company continues to report operating losses (preliminary operating loss of $7.5M-$8.5M in Q2).
- Cash burn remains high; company drew €12M from EIB facility in April 2026.
- BPH and endometriosis indications are still investigational in the U.S. with no guarantee of FDA clearance.
- Full financials (EPS, operating cash flow) not yet available, limiting visibility into bottom-line performance.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094134 |
| Document: tm2622525d2_8k.htm | 0001104659-26-094134 |
| Document: tm2622525d2_ex99-1.htm | 0001104659-26-094134 |
| Document: 0001104659-26-094134-index-headers.html | 0001104659-26-094134 |
| Document: 0001104659-26-094134-index.html | 0001104659-26-094134 |
| Document: 0001104659-26-094134.txt | 0001104659-26-094134 |
| 8-K Data (Synthetic) | 0001104659-26-094134 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 8-K | $4.36 $4.28 | ▲ +1.83% | ▼ −0.12% | $4.20 (+3.67%) |
Aug 14, 2026 7w ago | 8-K | $4.76 $4.11 | ▲ +13.66% | ▲ +11.66% | $4.20 (+11.76%) |
Aug 13, 2026 7w ago | 8-K | $4.76 $4.11 | ▼ −13.66% | ▼ −11.66% | $4.20 (−11.76%) |
Aug 12, 2026 7w ago | Press Release | $4.75 $4.16 | ▼ −12.42% | ▼ −10.52% | $4.20 (−11.58%) |
Aug 11, 2026 7w ago | 8-K | $4.75 $4.16 | ▼ −12.42% | ▼ −10.52% | $4.20 (−11.58%) |
Jul 30, 2026 9w ago | Press Release | $6.12 $4.31 | ▼ −29.58% | ▼ −32.56% | $4.20 (−31.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access